Susquehanna Fundamental Investments LLC Makes New $646,000 Investment in Orthofix Medical Inc. (NASDAQ:OFIX)

Susquehanna Fundamental Investments LLC bought a new stake in Orthofix Medical Inc. (NASDAQ:OFIX) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 37,006 shares of the medical device company’s stock, valued at approximately $646,000.

Several other large investors have also modified their holdings of the stock. Renaissance Technologies LLC raised its stake in Orthofix Medical by 166.9% during the fourth quarter. Renaissance Technologies LLC now owns 82,190 shares of the medical device company’s stock valued at $1,435,000 after buying an additional 51,399 shares in the last quarter. Barclays PLC raised its position in shares of Orthofix Medical by 38.8% during the 3rd quarter. Barclays PLC now owns 122,472 shares of the medical device company’s stock valued at $1,912,000 after acquiring an additional 34,210 shares in the last quarter. Kirr Marbach & Co. LLC IN bought a new position in Orthofix Medical during the fourth quarter worth $532,000. JPMorgan Chase & Co. lifted its stake in Orthofix Medical by 480.7% during the third quarter. JPMorgan Chase & Co. now owns 84,379 shares of the medical device company’s stock worth $1,318,000 after purchasing an additional 69,848 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Orthofix Medical in the fourth quarter worth $1,003,000. Institutional investors own 89.76% of the company’s stock.

Analysts Set New Price Targets

OFIX has been the topic of a number of recent research reports. StockNews.com upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating in a research report on Tuesday, February 25th. Roth Mkm reissued a “buy” rating and issued a $22.00 target price on shares of Orthofix Medical in a report on Wednesday, February 26th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $24.00 target price on shares of Orthofix Medical in a report on Wednesday, February 26th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $23.33.

Insider Buying and Selling at Orthofix Medical

In other Orthofix Medical news, insider Jorge Andres Cedron sold 3,816 shares of Orthofix Medical stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $13.31, for a total transaction of $50,790.96. Following the sale, the insider now owns 42,500 shares of the company’s stock, valued at $565,675. The trade was a 8.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Lucas Vitale sold 4,287 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $16.60, for a total value of $71,164.20. Following the completion of the transaction, the insider now directly owns 135,317 shares of the company’s stock, valued at approximately $2,246,262.20. The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 9,242 shares of company stock valued at $141,710 in the last ninety days. Company insiders own 2.60% of the company’s stock.

Orthofix Medical Stock Performance

Shares of OFIX opened at $13.79 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. Orthofix Medical Inc. has a 1 year low of $12.08 and a 1 year high of $20.73. The firm has a fifty day moving average of $15.34 and a 200-day moving average of $17.03. The company has a market cap of $538.11 million, a price-to-earnings ratio of -4.41 and a beta of 0.99.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.